Molycop acquisition dilutes near-term; synergies, margin expansion target long-term trajectory
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Equipment growth target cut from 25% to 15% mid-year; consumables delivered +20% YoY as guided; finance cost guidance missed materially but explained as Molycop debt.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Molycop acquisition is on track (14% EBITDA margin, early synergy wins) with clear 100 bps margin expansion and 15% CAGR consumables targets. But equipment business missed (guidance cut 25%→15%), finance costs remain 10× prior guidance, and adjusted profitability (₹452 Cr on ₹4,254 Cr = 10.6%) lags the 14.2% reported EBITDA due to leverage. Execution risk on synergies and near-term order flow.
₹4254 Cr
Revenue · +949.5% YoY₹-58.8 Cr
Reported PAT · −230.8% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Q2 consolidated revenue ₹4,254 Cr with EBITDA margin 14.2%
METDelivered revenue ₹4,254 Cr, EBITDA margin 14.2% — matches precisely
Equipment business +72% QoQ growth in Q2
MISSGrowth only sequential recovery from weak Q1 base; YoY equipment down ~5%; guidance explicitly revised DOWN from 25% to 15%
Adjusted PAT positive ₹452 Cr post one-times
METAdjusted PAT ₹452 Cr (0.8% adjusted margin) vs 11.5% reported OPM; net of ₹1,670 Cr loss includes ₹2,576 Cr transaction costs
Molycop delivered 14% EBITDA margin in first quarter
METThree-month adjusted EBITDA ₹554 Cr on ₹3,771.6 Cr revenue ≈ 14.7% — corroborates claim
Finance cost will normalize after non-core monetization in 12–18 months
OVERSTATEDH1 finance cost ₹4,086 Cr (~₹2,043 Cr per quarter) dwarfs prior ₹110–120 Cr FY27 guidance; no committed timeline for relief
Consumables grew 20% YoY in H1
METH1 consumables ₹9,143 Cr vs ₹7,614 Cr prior year = +20.1% YoY — supported
Earnings quality
What changed since the last call
Equipment growth guidance cut 25%→15%
DowngradeExplicit revision. Prior call guided 25% equipment growth; Q2 only +2% sequentially post -5% H1 YoY. Customers delayed orders to next quarter.
Molycop added; first-quarter EBITDA delivered 14%
NewMolycop brought into consolidation June 1, 2026. Three-month adjusted EBITDA ₹554 Cr on ₹3,771 Cr revenue = 14.7%, within Tegastrike zone near legacy EBITDA guidance of ~15%.
Finance cost materially above FY27 guide
DowngradePrior guidance ₹110–120 Cr FY27 annual (≈₹27.5–30 Cr quarterly). Actual H1 ₹4,086 Cr (₹2,043 Cr per quarter) includes Molycop debt, preference dividend, acquisition-driven leverage. Management says monetization 12–18 months.
Molycop day-one cross-sell secured: 500-ton trial grinding media order
NewEarly win from Molycop trial supply to existing Tega mill-lining customer. Opportunity to scale to 20,000–30,000 tons, termed 'big game-changer' for combined platform.
The Q&A
Analysts pressed hard on equipment guidance cut and finance costs. Mehul deferred specifics on finance cost relief timeline; Tushar forced acknowledgment that Molycop growth flat YoY and equipment margins 'relatively flat' despite 14% goal. Grasberg and Cobre Panamá customer disclosures withheld (confidentiality cited). No major deflection but tone cautious, not confident.
Molycop volume growth — Tushar Khurana, Peace Wealth
PartialPatrick Koley: Three-month growth relatively flat; four-month +2.2%. Margins evaluated per-ton on sales basis, not rate-of-return; we anticipate margins relatively flat vs prior year given steel price leverage and synergies ahead.
Equipment business deterioration — Tushar Khurana, Peace Wealth
AnsweredMehul Mohanka: Order book is healthy, what is dragging performance is revenue, not order book. Customers have pushed orders to next quarter. Awaiting customer confirmations to convert. Expected strong rebound H2. We expect Q3, Q4 to come back very strongly.
Equipment EBITDA margin path — Chirag Muchhala, Centrum Broking
PartialMehul Mohanka: Order book healthy. Revenue is the constraint due to project-intensive nature and customer approvals pending shipment. Equipment margins historically strong; we expect Q3, Q4 strong rebound.
Finance cost guidance — Tushar Khurana, Peace Wealth
PartialMehul Mohanka: Monetization of non-core assets underway; difficult to timeline precisely, but 12–18 month exercise. We will see some come-through in this fiscal, more next. Once non-core sales and leverage reduction, finance costs will improve. Ravi Joshi: Too early for line-by-line guidance; will sharpen over time with asset sales.
Consumables CAGR and Chile capex — Varun Jain, Dolat Capital
AnsweredHimanshu Raijada: Chile on track for January startup and March commercial production. No additional revenue anticipated in FY28; plant is built for sustenance of next 4–5 years to support 15% CAGR consumables growth, subsumed in that guidance.
Grasberg mine recovery and Cobre Panamá — Tushar Khurana, Peace Wealth
DodgedPatrick Koley: Due to confidentiality, we do not divulge specific volumes for customers. Lance Dawber: Grasberg performance increasing, moving toward more reflective normalized operations. Cobre Panamá Interministerial Commission delivered feasibility report on potential restart. Contingent payments do not trigger unless mining permits restored.
Margins 2+ years forward — Raman KV, Sequent Investments
PartialHimanshu Raijada: EBITDA margin will improve by 100 bps as we scale and synergies benefit quarters to come. Molycop and Tega combined, with growth journey, operating leverage will come into play and margins will expand. Equipment business is project-intensive; expected to maintain healthy margins long term.
Cross-selling and Molycop synergy scale-up — Sagar Shetty, Wealthwia
AnsweredMehul Mohanka: 500 tons of grinding media secured as trial order with existing mill-lining customer. Opportunity to scale 20,000–30,000 tons once trial passes. Just four months post-transaction; big game-changer for combined portfolio. Multiple initiatives in pipeline across geographies.
Consolidated margin outlook 3–5 years — Varinder Bansal, Omkara Capital
PartialMehul Mohanka: Currently ~14% consolidated margin. With transaction culminated and Molycop synergies to flow, I see margins trending 17%–18% in 3–5 years. Vision is 17%–18%, delivery timeline flexible; math says margins will uplift as we continue to deliver.
Guidance
Consumables 15% CAGR long-term (H2 onwards)
HighH1 achieved +20% YoY; Chile grinding facility Jan 2027 startup for capacity expansion supporting this CAGR
Equipment growth 15% (revised down from 25%)
LowExplicit revision mid-year. Customers pushing orders to H2; equipment H1 only -5% YoY. Management expects 'strong rebound' H2 and Q3, Q4 'very strong' but no quantified guidance
Consolidated EBITDA margin ~15% (long-term); 100 bps expansion over coming year
MediumQ2 delivered 14.2% (slightly below 15% target). Four initiatives to drive margin: GCC setup, HQ relocation, SG&A cuts, operating efficiency improvements
Molycop EBITDA margin: 'relatively flat' near current 14%, benefiting from synergies over quarters to come
MediumQ2 achieved 14.7% on three months post-acquisition. Analyst pressed on margin expansion path; management vague on timing and magnitude
Capital expenditure disciplined, focused on high-return projects; Chile facility Jan 2027 commercial
HighCapex H2 FY27 ₹5 million; trailing 12-month ₹28.9 Cr. Management flagged: Molycop targeting investment in strategic capex for growth; will be disciplined
Risks the call surfaced
Customer order delays
HighEquipment business revenue dragged by customers pushing orders to next quarter, causing H1 -5% YoY and +2% QoQ only. Guidance cut 25%→15%. Rebound expected H2 but unconfirmed.
Finance cost overshoot vs guidance
HighH1 finance cost ₹4,086 Cr (~₹2,043 Cr per quarter) vs prior ₹110–120 Cr FY27 annual guidance (~₹27.5 Cr quarterly). Molycop acquisition debt and preference dividend drove spike. Non-core monetization 12–18 months timeline vague; may delay relief into FY28.
Molycop mine customer concentration
MediumGrasberg (Indonesia) and Cobre Panamá are large Molycop customers. Grasberg only at 67% normalized throughput post-September 2025 mudslide; recovery to 80% by mid-2027 uncertain. Cobre Panamá permitting uncertain; contingent payments linked to mining restart.
Equipment EBITDA margin recovery unproven
MediumEquipment business Q1 reported negative EBITDA; Q2 only modest growth +2% sequentially. Historically delivered 20%+ margins. Current trajectory suggests difficulty returning to historical margin levels. Order book healthy but margins depend on project mix and customer acceptance of product.
Molycop cross-selling early-stage
LowSynergy target USD 20M over 2–2.5 years. First cross-sell win only 500-ton grinding media trial with existing customer. Scaling to 20,000–30,000 tons is aspirational but not committed. Integration risk if synergies do not materialize as guided.
Management
Score 6/10. Transparent on one-time items and acquisition mechanics. Evasive on customer-specific data (Grasberg, Cobre Panamá witheld). Candid on equipment guidance cut. Finance cost timeline vague. Consumables +20% YoY (beat). Equipment -5% YoY (miss). Finance cost ₹4,086 Cr H1 vs ₹110–120 Cr FY27 guidance (major miss). Molycop integration on track with 14.7% EBITDA achieved in one quarter.
1 · Q3 FY27
Equipment order book conversion; H1 impact of order delays; finance cost trajectory clarity
2 · Jan 2027
Chile grinding media facility commercial production start; first new-build synergy revenue
3 · H2 FY27
Cross-selling progress (500t trial scale-up); Grasberg mine recovery (67% normalized run rate in Q2)
Execution risk on synergies and near-term order flow.
Tega Industries swings to ₹58.8 Cr consolidated loss as Molycop financing costs bite
PAT -230.8% YoY · revenue +949.5% · margins compressing · miss vs street
₹4,254.04 Cr
+949.5% YoY
₹-58.77 Cr
-230.8% YoY
-1.37%
-12pp YoY
₹-6.32
Tega Industries' consolidated results (the primary basis) swung to a net loss of ₹58.8 Cr for Q2 FY27, against a profit of ₹44.9 Cr in the year-ago quarter and a narrower loss of ₹108.3 Cr in Q1 FY27. Revenue surged to ₹4,254 Cr, up ~950% YoY and ~147% QoQ, but the jump is almost entirely the arithmetic effect of consolidating Molycop Group (acquired 1 June 2026) for a full quarter versus one month in Q1 and not at all a year ago — not organic growth. Standalone (holding company only) revenue was ₹202.7 Cr with a ₹2.3 Cr loss, underscoring that both the scale-up and the loss sit almost entirely at the consolidated, Molycop-driven level.
Q2 FY-2027 vs prior quarters
The consolidated loss was driven by finance costs of ₹291.9 Cr for the quarter (₹408.6 Cr for H1 FY27) on acquisition debt — against management's own FY27 guidance of just ₹110-120 Cr for the FULL YEAR, already overshot nearly 4x within six months — plus depreciation and amortisation of ₹168.6 Cr (from ₹5.7 Cr a year ago) on purchase-accounting intangibles (₹347.2 Cr of acquired intangibles and ₹505.7 Cr of goodwill recognised on the deal). A further ₹66.6 Cr of one-time acquisition/integration expense sits inside 'other expenses' this quarter (₹257.6 Cr for H1). Stripping that one-off out, adjusted PAT would be roughly +₹7.8 Cr — still down about 83% YoY from ₹44.9 Cr, showing the underlying drag is the acquisition financing and amortisation load, not just transaction costs. Segment EBITDA margin was ~13.1% of revenue, below management's ~15% consolidated EBITDA guidance and down from ~17.1% a year ago — margins are compressing broadly as guided (Molycop structurally dilutes the legacy consumables margin) but running a touch below even that diluted target.
The stock went into the print at ₹1,772, down 15.3% over the past month of trading.
For context: revenue is at a 6-quarter high.
Consumables at 15% long-term CAGR; consolidated EBITDA margin ~15%; USD 20M Molycop synergies over 2–2.5 years; FY27 finance cost ₹110–120 Cr.
— This quarter: missed
We have no specific Street PAT estimate for this quarter, but full-year FY27 consensus (per stockanalysis.com) pegs EPS near ₹33 and PAT growth of 15-20% — a bar that looks difficult after a consolidated net loss of ₹167.0 Cr for H1 FY27 alone, so we mark this a miss against the implied full-year path. Management's prior guidance also flagged Consumables growing at a 15% long-term CAGR and USD 20M of Molycop synergies over 2-2.5 years; one quarter post-acquisition-close is too early to test either, and we flag both as unresolved rather than met or missed. During the quarter the company completed a ₹95.4 Cr preferential allotment of 4.78 lakh shares (October 15) and a subsidiary won a Calcutta High Court case against the Income Tax department (October 16) — neither materially moves this quarter's P&L.
W1
Finance-cost trajectory: H1 FY27 already at ₹408.6 Cr against a full-year guided ₹110-120 Cr — watch for a revised FY27 guidance number next quarter.
W2
Molycop integration: USD 20M synergy target over 2-2.5 years and EBITDA margin trending back toward the guided ~15% from the current ~13.1%.
W3
Loss-narrowing trend: consolidated loss fell from ₹108.3 Cr (Q1 FY27) to ₹58.8 Cr (Q2 FY27) — watch whether Q3 FY27 continues toward breakeven.
Consolidated PAT -58.77 Cr is the total for the period (before NCI split): owners' share -47.47 Cr, NCI -11.31 Cr; EPS -6.32 is based on owners' share. Includes ₹6.66 Cr one-time Molycop acquisition expense (standalone) and ₹66.60 Cr (consolidated) inside 'other expenses', per Note 3/4. Standalone total income (212.96) vs revenue+other income (213.02) shows a minor ~₹0.06 Cr rounding gap in the source table. Both statements are Unaudited/reviewed, clean legible tables.
Molycop Masks the Real Issue: Equipment Missed, Finance Costs Stay Elevated
Reported loss of ₹1,670 Cr obscures an adjusted profit of ₹452 Cr and a functioning acquisition. The real story is that equipment guidance was cut 25% to 15% and finance costs remain ₹4,086 Cr in H1—10 times prior guidance. That's the problem management hasn't solved.
-₹1,670 Cr
includes ₹2,576 Cr acquisition costs
₹452 Cr
10.6% margin (organic)
14.2%
-80 bps vs 15% target
14.7%
first quarter post-acquisition
The gap: reported vs. adjusted
Tega's Q2 loss of ₹1,670 Cr is almost entirely one-time: ₹2,576 Cr in acquisition costs, ₹117 Cr in inventory step-up, and ₹1,235 Cr in tax charges related to the Molycop consolidation. Strip these, and adjusted PAT is ₹452 Cr on ₹4,254 Cr revenue—a 10.6% margin. That's the organic number. But Molycop itself is only three months into consolidation and delivered 14.7% EBITDA on ₹3,771.6 Cr revenue. The company is functioning; the math is obscured.
What the call claims, and what holds up
Molycop delivered 14% EBITDA margin in first quarter
SupportedThree-month adjusted EBITDA ₹554 Cr on ₹3,771.6 Cr = 14.7% margin
Equipment business +72% QoQ growth in Q2
ContradictedSequential recovery from weak Q1 base; YoY down 5%. Guidance cut from 25% to 15% due to customer order delays.
Consumables grew 20% YoY in H1
SupportedH1 consumables ₹9,143 Cr vs ₹7,614 Cr prior = +20.1% YoY
Finance costs will normalize after non-core monetization in 12–18 months
OverstatedH1 finance cost ₹4,086 Cr vs prior ₹110–120 Cr FY27 guidance (~₹27.5 Cr quarterly). No committed timeline for relief.
What changed on this call
Equipment guidance cut 25% → 15%. Explicit mid-year revision. Customers have pushed orders to next quarter; management expects 'strong rebound' H2 but no quantified timeline.
Molycop added June 1; delivered 14.7% EBITDA in first three months. Within legacy guidance zone (~15%). Integration mechanics on track: 500-ton grinding media trial secured with existing Tega mill-liner customer.
Finance cost guidance completely missed. Prior: ₹110–120 Cr FY27 annual. Actual: ₹4,086 Cr H1 (₹2,043 Cr per quarter). Includes ₹500 Cr preference dividend and Molycop acquisition debt. Monetization timeline vague.
Grasberg mine recovery at 67% of normal throughput. Contingent upside if recovery accelerates toward 80% by mid-2027. Cobre Panamá contingent payments hinge on mining permit restoration.
The bull-bear ledger
Molycop at 14.7% EBITDA delivered on first quarter; within long-term target zone
Consumables +20% YoY beats long-term 15% CAGR guidance; margin expansion to 22.4%
Order book ₹13,976 Cr (+14% QoQ) provides H2 revenue visibility
Equipment guidance cut signals softness; only +2% QoQ, -5% YoY despite healthy order book
Finance costs ₹4,086 Cr H1 (10× prior guidance); adjusted PAT margin 10.6% lags reported EBITDA due to leverage
Molycop cross-selling early-stage: 500-ton trial is proof-of-concept, not committed revenue; target 20,000–30,000 tons is aspirational
Equipment EBITDA negative Q1, flat margins Q2; margin recovery unproven despite order book
Street positioning
Tega's stock sits at ₹1,678.1, 27.94% below its all-time high and trading below its SMA20, SMA50, and SMA200—a meaningful drawdown that reflects the market's skepticism. The RSI of 41.1 signals neutral momentum, but volume is increasing, suggesting institutional attention. FII ownership rose 66 basis points QoQ to 2.80% (still cautious), while DII remains steady at 18.68%. The post-result price action has not held—the market did not reward the Molycop integration story, likely pricing in near-term execution risk on equipment recovery and the unresolved finance cost question. The discount to ATH is not an opportunity play; it's the market pricing in that equipment guidance cut and elevated leverage are real headwinds that won't resolve until H2 FY27 or later.
Risks, ranked by severity to a holder
Equipment order book conversion failure
HighGuidance cut from 25% to 15% mid-year due to customer order delays. Equipment revenue dragging (H1 -5% YoY, +2% QoQ only). If H2 rebound doesn't materialize, FY27 guidance will miss and margins remain depressed.
Finance costs remain 10× prior guidance with vague relief timeline
High₹4,086 Cr H1 (₹2,043 Cr per quarter) vs prior ₹110–120 Cr FY27 annual. Non-core asset monetization timeline is 12–18 months (vague). If delayed, debt reduction pushes into FY28 and adjusted margins stay under 11%.
Equipment EBITDA collapse Q1, flat Q2—margin recovery unproven
MediumQ1 negative EBITDA, Q2 only +2% QoQ growth. Order book healthy but project-intensive nature suggests execution dependent. If margins don't recover to 20%+ historically, blended Tega-Molycop targets become at risk.
Molycop customer concentration: Grasberg at 67% throughput, Cobre Panamá permitting uncertain
MediumTwo customers represent meaningful upside (and downside) to Molycop revenue. Grasberg recovery to 80% by mid-2027 not guaranteed; Cobre Panamá contingent on mining permit. Downside could dampen Molycop volume growth below guidance.
Molycop cross-selling early-stage: 500-ton trial unproven at scale
LowSynergy target USD 20M over 2–2.5 years. First cross-sell win is 500-ton grinding media trial with existing customer. Scaling to 20,000–30,000 tons is aspirational. If trials fail, synergy realization delays and margin expansion timeline extends.
1 · Equipment order book conversion and H2 revenue ramp
Management flagged 'strong rebound' expected in Q3 and Q4. Equipment H1 was only +2% QoQ; order book at ₹13,976 Cr should be convertible if customer approvals clear. This is the near-term make/break for the quarter-to-quarter narrative.
2 · Non-core asset monetization and finance cost trajectory
CFO Ravi Joshi said 12–18 month monetization window but no committed assets or timeline yet. Any concrete announcement of asset sales and paydown of ₹500 Cr+ of Molycop debt would validate the management narrative and ease the 10× finance cost overshoot.
3 · Chile grinding facility commercial startup and consumables scaling
Facility targeted for Jan 2027 commercial production. If on track and Tega successfully scales the 500-ton grinding media trial to 5,000+ tons in H2, that validates the synergy story and proves cross-selling is not just talk.
The number to track from here
Reported EBITDA margin of 14.2% is now the legacy KPI. Going forward, track two: (1) Equipment sequential revenue growth and margin expansion—if H2 doesn't see +10% QoQ revenue and margins north of 15%, the miss extends into FY28. (2) Adjusted PAT margin on a quarterly basis (ex-one-times, ex-Molycop integration costs). The path back to 11%+ adjusted margins (vs 10.6% in Q2) depends entirely on equipment recovery and leverage reduction. Molycop is performing; the company's near-term credibility hinges on equipment execution and finance cost relief.
Tega's acquisition of Molycop was the right move strategically—the combined platform has scale, synergy potential, and consumables growth on track. But it was also a leverage move: adjusted PAT margin dropped from legacy 11%+ (pre-acquisition) to 10.6% post-acquisition due to ₹4,086 Cr in finance costs. That gap is the story of the quarter, not the Molycop integration itself.
Near-term is a steady execution play, not a step-change. Equipment demand has to stabilize in H2 (order book is there; customers are delaying, not canceling). Finance costs have to normalize via non-core asset sales starting in H2. Long-term thesis—15% EBITDA margin, 15% consumables CAGR, USD 20M synergies—is intact but execution timeline extends. The stock's 27.94% discount to ATH is not a bargain; it's a fair repricing of the execution risk ahead. Hold for management to prove equipment recovery and asset sales. Upgrade only if H2 equipment revenue confirms and finance cost relief materializes.